


Pharmaceuticals & Biotechnology | Small Cap
Morepen Laboratories Ltd demonstrates a mixed financial performance. The company shows exceptional solvency and growth, driven by minimal debt and robust expansion in revenue, profits, and assets. Profitability is also a strong point, with impressive returns on capital, equity, and assets, alongside healthy margins. However, efficiency in asset utilization is a concern, as indicated by lower turnover ratios and longer inventory holding periods. The company's liquidity is reasonable, though there are some weaknesses noted in cash flow management. Furthermore, financial metrics such as earnings per share, book value, and capital expenditure need attention. Overall, Morepen Laboratories exhibits solid financial health, but improvements in operational efficiency and financial management could further enhance its performance.
Morepen Laboratories Ltd demonstrates a mixed financial performance. The company shows exceptional solvency and growth, driven by minimal debt and robust expansion in revenue, profits, and assets. Profitability is also a strong point, with impressive returns on capital, equity, and assets, alongside healthy margins. However, efficiency in asset utilization is a concern, as indicated by lower turnover ratios and longer inventory holding periods. The company's liquidity is reasonable, though there are some weaknesses noted in cash flow management. Furthermore, financial metrics such as earnings per share, book value, and capital expenditure need attention. Overall, Morepen Laboratories exhibits solid financial health, but improvements in operational efficiency and financial management could further enhance its performance.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
65.64
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
45.91
P/B RATIO
3.48
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
2.34
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
0.00
EV/EBITDA RATIO
25.04
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹79.42 as on Aug 6, 2026.
The company demonstrates excellent growth across various metrics. Revenue, operating profit, EPS, asset, and net income growth rates are all strong, reflecting the company's robust expansion and increasing profitability. This indicates the company is effectively capitalizing on market opportunities and generating significant value for its stakeholders. The consistent positive growth trend suggests a promising outlook for future performance.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 30.22 | -8.34 | 19.18 | 7.22 | -0.33 |
| Operating Profit Growth Rate | 15.13 | -41.61 | 98.75 | 9.43 | -27.59 |
| Earnings Per Share (EPS) Growth | -1.39 | -64.32 | 147.37 | 14.36 | -19.53 |
| Asset Growth Rate | 24.71 | 3.74 | 16.49 | 37.51 | 8.89 |
| Net Income Growth Rate | 5.15 | -61.76 | 148.72 | 21.65 | -18.64 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 37.02 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 73.76 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Windlas Biotech Ltd | 7.52 | 27.76 | Neutral | 105.00 | 32.19 | 66.00 |
| 4 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.81 | Neutral | 98.00 | 43.88 | 88.00 |
| 5 | RPG Life Sciences Ltd | 7.12 | 38.61 | Neutral | 147.00 | 69.64 | 115.00 |
| 6 | Morepen Laboratories Ltd | 7.12 | 45.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 7 | Alembic Ltd | 7.06 | 7.01 | Undervalued | 90.00 | 4.85 | 317.00 |
| 8 | Syncom Formulations (India) Ltd | 6.92 | 16.27 | Undervalued | 77.00 | 0.81 | 76.00 |
| 9 | Hester Biosciences Ltd | 6.54 | 37.59 | Neutral | 87.00 | 61.24 | 57.00 |
| 10 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 11 | SMS Pharmaceuticals Ltd | 5.94 | 32.80 | Neutral | 171.00 | 9.35 | 102.00 |
| 12 | Gufic BioSciences Ltd | 5.49 | 63.18 | Neutral | 151.00 | 6.30 | 64.00 |
| 13 | Dishman Carbogen Amcis Ltd | 5.38 | 31.30 | Neutral | 566.00 | -2.45 | 97.00 |
| 14 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 34.79 | Undervalued | 269.00 | 4.69 | 138.00 |
| 15 | Indoco Remedies Ltd | 5.26 | -21.52 | Neutral | 142.00 | -0.61 | -99.00 |
| 16 | Solara Active Pharma Sciences Ltd | 4.34 | -249.32 | Neutral | 187.00 | -1.50 | -7.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral